JP2014513716A - 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用 - Google Patents

鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用 Download PDF

Info

Publication number
JP2014513716A
JP2014513716A JP2014510900A JP2014510900A JP2014513716A JP 2014513716 A JP2014513716 A JP 2014513716A JP 2014510900 A JP2014510900 A JP 2014510900A JP 2014510900 A JP2014510900 A JP 2014510900A JP 2014513716 A JP2014513716 A JP 2014513716A
Authority
JP
Japan
Prior art keywords
testosterone
gel formulation
gel
formulation
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014510900A
Other languages
English (en)
Japanese (ja)
Inventor
クレップナー，ウェイン
フォガーティ，シヴォーン
オベレガー，ワーナー
マエ，ポール，ジョゼ，ピエール，マリー
Original Assignee
トリメル バイオファーマ エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トリメル バイオファーマ エスアールエル filed Critical トリメル バイオファーマ エスアールエル
Publication of JP2014513716A publication Critical patent/JP2014513716A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014510900A 2011-05-15 2012-05-15 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用 Pending JP2014513716A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161486324P 2011-05-15 2011-05-15
US61/486,324 2011-05-15
US201161486634P 2011-05-16 2011-05-16
US61/486,634 2011-05-16
PCT/IB2012/001112 WO2012156820A1 (en) 2011-05-15 2012-05-15 Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018158566A Division JP2018199701A (ja) 2011-05-15 2018-08-27 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用

Publications (1)

Publication Number Publication Date
JP2014513716A true JP2014513716A (ja) 2014-06-05

Family

ID=46579248

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2014510901A Expired - Fee Related JP6152092B2 (ja) 2011-05-15 2012-05-15 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
JP2014510900A Pending JP2014513716A (ja) 2011-05-15 2012-05-15 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2017056679A Expired - Fee Related JP6594924B2 (ja) 2011-05-15 2017-03-22 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
JP2018158566A Pending JP2018199701A (ja) 2011-05-15 2018-08-27 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2019173990A Active JP7017254B2 (ja) 2011-05-15 2019-09-25 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
JP2020012807A Pending JP2020079257A (ja) 2011-05-15 2020-01-29 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2020157216A Pending JP2021001206A (ja) 2011-05-15 2020-09-18 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2022034334A Pending JP2022078222A (ja) 2011-05-15 2022-03-07 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2022076671A Pending JP2022105175A (ja) 2011-05-15 2022-05-06 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014510901A Expired - Fee Related JP6152092B2 (ja) 2011-05-15 2012-05-15 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2017056679A Expired - Fee Related JP6594924B2 (ja) 2011-05-15 2017-03-22 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
JP2018158566A Pending JP2018199701A (ja) 2011-05-15 2018-08-27 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2019173990A Active JP7017254B2 (ja) 2011-05-15 2019-09-25 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
JP2020012807A Pending JP2020079257A (ja) 2011-05-15 2020-01-29 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2020157216A Pending JP2021001206A (ja) 2011-05-15 2020-09-18 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2022034334A Pending JP2022078222A (ja) 2011-05-15 2022-03-07 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
JP2022076671A Pending JP2022105175A (ja) 2011-05-15 2022-05-06 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用

Country Status (16)

Country Link
EP (3) EP2709588B1 (enExample)
JP (9) JP6152092B2 (enExample)
KR (10) KR20190117803A (enExample)
CN (4) CN110613679A (enExample)
AR (2) AR089553A1 (enExample)
AU (11) AU2012257490A1 (enExample)
BR (2) BR112013029336B1 (enExample)
CA (3) CA2836398C (enExample)
DK (1) DK2714006T3 (enExample)
EA (1) EA201391701A1 (enExample)
ES (1) ES2859784T3 (enExample)
IL (2) IL229400A0 (enExample)
MX (4) MX363561B (enExample)
PL (1) PL2714006T3 (enExample)
WO (2) WO2012156820A1 (enExample)
ZA (2) ZA201309264B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015222994A (ja) * 2011-05-31 2015-12-10 クアルコム，インコーポレイテッド Ｎｆｃアクティブ化およびデータ交換報告機構を向上させるための方法および装置
JP2019505583A (ja) * 2016-01-07 2019-02-28 ヴィラマル リミテッド 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法
JP2022517724A (ja) * 2018-12-14 2022-03-10 アセラス バイオファーマ インコーポレーテッド テストステロンの活性エステル誘導体、組成物、およびそれらの使用
JP2023550422A (ja) * 2020-11-19 2023-12-01 アコージア セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 非水性ゲル組成物
US12016953B2 (en) 2018-11-30 2024-06-25 Viramal Limited Method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
CA2836398C (en) * 2011-05-15 2021-12-14 Trimel Biopharma Srl Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
WO2014076569A2 (en) * 2012-11-14 2014-05-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
US20140171918A1 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
JP6338658B2 (ja) * 2013-10-07 2018-06-06 アンタレス・ファーマ・インコーポレーテッド テストステロンの針補助ジェット注射を通じたヘマトクリット調節
JP2017513809A (ja) 2014-02-19 2017-06-01 アンタレス・ファーマ・インコーポレーテッド テストステロン組成物の針に補助されるジェット注射投与
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
TW201636045A (zh) * 2015-01-28 2016-10-16 波美西恩製藥有限責任公司 組成物、促進或增強受試者之局部毛髮飽滿度及厚度或毛髮生長之方法、包括該組成物之套組及裝置
US20160374800A1 (en) * 2015-06-29 2016-12-29 Changcheng You Implantable scaffolds for treatment of sinusitis
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR102015020878B1 (pt) * 2015-08-28 2019-08-27 F B M Ind Farmaceutica Ltda formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona.
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CN109069750B (zh) 2016-04-25 2021-09-07 科斯卡家族有限公司 药物输送系统
WO2017208072A2 (en) * 2016-06-02 2017-12-07 Acerus Pharmaceutical Corporation Nasal cannabidiol compositions
EA201892595A1 (ru) 2016-06-03 2019-06-28 М Эт П Фарма Аг Назальные фармацевтические композиции с пористым наполнителем
CA3050361A1 (en) * 2017-01-20 2018-07-26 M et P Pharma AG Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
EP3641424B1 (en) 2017-06-17 2022-05-04 LG Electronics Inc. Method for registering a user equipment with a network slice in a wireless communication system and user equipment therefor
CN111615409A (zh) 2017-11-17 2020-09-01 科斯卡家族有限公司 用于流体输送歧管的系统和方法
US11234928B2 (en) * 2017-11-27 2022-02-01 Aska Pharmaceutical Co., Ltd. Powder preparation for nasal administration
PL3710012T3 (pl) 2018-02-02 2025-11-17 Acerus Biopharma Inc. Sposoby terapii testosteronem
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
CN108771622B (zh) * 2018-07-11 2022-01-07 尹振图 一种自闭式针形滴嘴及眼药水瓶
BR112021007877A2 (pt) 2018-10-26 2021-08-03 Viramal Limited composição em gel mucoadesiva
US20200170962A1 (en) 2018-11-30 2020-06-04 F. Markus Leweke Nasal cannabidiol compositions
USD1052082S1 (en) 2020-06-01 2024-11-19 Koska Family Limited Sealed fluid container
CN112121049B (zh) * 2020-08-28 2022-02-01 嘉兴市第一医院 顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用
GB202307501D0 (en) * 2023-05-19 2023-07-05 Lawley Pharmaceuticals Pty Ltd Process for preparing dispensable testosterone cream

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524589A (ja) * 2003-03-11 2007-08-30 アンタレス ファルマ イーペーエル アクチェンゲゼルシャフト 活性薬の経皮又は経粘膜適用のための使用及び製剤
JP2008522997A (ja) * 2004-12-09 2008-07-03 バイエル・ヘルスケア・アクチェンゲゼルシャフト 酸によるグルココルチコイドエステルの安定化
US20100311707A1 (en) * 2003-11-11 2010-12-09 Claudia Mattern Controlled release delivery system for nasal applications and methods of treatment

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
DE4214953C2 (de) 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels
US5756071A (en) 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5576071A (en) 1994-11-08 1996-11-19 Micron Technology, Inc. Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds
JP2000514065A (ja) * 1997-07-03 2000-10-24 アルザ コーポレイション ドラッグデリバリーディバイスとその製造法
BR9814014B1 (pt) * 1997-11-10 2014-10-07 Strakan Int Ltd Composição para aplicação tópica tendo propriedades de melhora da penetração
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10064950A1 (de) * 2000-12-23 2002-07-11 Impetus Ag Basel Thixotropes Nasenspray
JP2005505587A (ja) * 2001-10-12 2005-02-24 シーエヌエス・インコーポレーテッド 含水性の点鼻ゲル及びその塗布装置
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
ATE534373T1 (de) * 2003-10-10 2011-12-15 Antares Pharma Ipl Ag Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
EP1896038B1 (en) * 2005-06-03 2016-11-09 Acrux DDS Pty Ltd Method and composition for testosterone transdermal delivery
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
CN101099742A (zh) * 2006-07-06 2008-01-09 上海富海科申药业有限公司 能够减少皮肤刺激的睾酮凝胶制剂
ES2358619T3 (es) * 2006-10-04 2011-05-12 M & P PATENT AKTIENGESELLSCHAFT Sistema de administración de liberación controlada para aplicación nasal de neurotransmisores.
AU2008231781B2 (en) * 2007-03-23 2012-09-20 Besins Healthcare Luxembourg Sarl Compositions and method for treating pediatric hypogonadism
JP4825305B2 (ja) * 2007-09-20 2011-11-30 株式会社 資生堂 経皮吸収製剤
EP2949361B1 (en) * 2007-11-13 2017-03-22 Athenion AG C-19 steroids for treating cellulite
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
CA2836398C (en) * 2011-05-15 2021-12-14 Trimel Biopharma Srl Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524589A (ja) * 2003-03-11 2007-08-30 アンタレス ファルマ イーペーエル アクチェンゲゼルシャフト 活性薬の経皮又は経粘膜適用のための使用及び製剤
US20100311707A1 (en) * 2003-11-11 2010-12-09 Claudia Mattern Controlled release delivery system for nasal applications and methods of treatment
JP2008522997A (ja) * 2004-12-09 2008-07-03 バイエル・ヘルスケア・アクチェンゲゼルシャフト 酸によるグルココルチコイドエステルの安定化

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE AGING MALE, vol. 11, no. 4, JPN6016010319, 2008, pages 171 - 178, ISSN: 0003279175 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015222994A (ja) * 2011-05-31 2015-12-10 クアルコム，インコーポレイテッド Ｎｆｃアクティブ化およびデータ交換報告機構を向上させるための方法および装置
JP2019505583A (ja) * 2016-01-07 2019-02-28 ヴィラマル リミテッド 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法
JP7055754B2 (ja) 2016-01-07 2022-04-18 ヴィラマル リミテッド 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法
JP2022088646A (ja) * 2016-01-07 2022-06-14 ヴィラマル リミテッド 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法
US12016953B2 (en) 2018-11-30 2024-06-25 Viramal Limited Method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent
JP2022517724A (ja) * 2018-12-14 2022-03-10 アセラス バイオファーマ インコーポレーテッド テストステロンの活性エステル誘導体、組成物、およびそれらの使用
JP2023550422A (ja) * 2020-11-19 2023-12-01 アコージア セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 非水性ゲル組成物
JP7620703B2 (ja) 2020-11-19 2025-01-23 アコージア セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 非水性ゲル組成物

Also Published As

Publication number Publication date
WO2012156820A9 (en) 2014-02-20
CN103796636B (zh) 2019-04-05
JP2017160204A (ja) 2017-09-14
ZA201309265B (en) 2016-01-27
CA3034552C (en) 2023-02-07
AU2019201618A1 (en) 2019-04-18
AR089553A1 (es) 2014-09-03
WO2012156822A1 (en) 2012-11-22
ES2859784T3 (es) 2021-10-04
WO2012156820A1 (en) 2012-11-22
JP2022078222A (ja) 2022-05-24
JP6594924B2 (ja) 2019-10-23
CN109481394B (zh) 2023-05-05
JP2022105175A (ja) 2022-07-12
IL229400A0 (en) 2014-01-30
EP2714006A1 (en) 2014-04-09
PL2714006T4 (pl) 2021-08-16
CN103796636A (zh) 2014-05-14
MX2013013388A (es) 2014-09-15
AU2017204182A1 (en) 2017-07-20
AU2022202402A1 (en) 2022-05-12
CA2836405C (en) 2021-09-07
EP2709588A1 (en) 2014-03-26
KR20140045400A (ko) 2014-04-16
AU2020210227A1 (en) 2020-08-20
MX363561B (es) 2019-03-27
CN103813784A (zh) 2014-05-21
JP2020079257A (ja) 2020-05-28
KR20210135003A (ko) 2021-11-11
BR112013029336B1 (pt) 2021-11-30
KR20210029849A (ko) 2021-03-16
MX2019003340A (es) 2019-07-04
MX2013013369A (es) 2014-10-17
EA201391701A1 (ru) 2014-04-30
AU2020267162A1 (en) 2020-12-03
MX2020008599A (es) 2022-08-31
KR20190006194A (ko) 2019-01-17
ZA201309264B (en) 2015-09-30
JP2021001206A (ja) 2021-01-07
MX374398B (es) 2025-03-06
EP2709588B1 (en) 2021-08-25
AU2012257492A1 (en) 2013-12-19
AU2024216312A1 (en) 2024-10-24
KR102568894B1 (ko) 2023-08-21
CN110613679A (zh) 2019-12-27
KR20230041081A (ko) 2023-03-23
KR20140033408A (ko) 2014-03-18
CA2836398A1 (en) 2012-11-22
AU2020267162B2 (en) 2022-06-09
JP2014515038A (ja) 2014-06-26
AU2017203470A1 (en) 2017-06-22
KR20190117803A (ko) 2019-10-16
AU2019203400A1 (en) 2019-08-01
EP3977982A1 (en) 2022-04-06
JP6152092B2 (ja) 2017-06-28
KR102088038B1 (ko) 2020-03-13
KR20200028503A (ko) 2020-03-16
JP7017254B2 (ja) 2022-02-08
KR20240162608A (ko) 2024-11-15
PL2714006T3 (pl) 2021-08-16
JP2020073469A (ja) 2020-05-14
DK2714006T3 (da) 2021-03-15
IL229401A0 (en) 2014-01-30
BR112013029332A2 (pt) 2021-06-01
MX395212B (es) 2025-03-21
AR086409A1 (es) 2013-12-11
JP2018199701A (ja) 2018-12-20
CA2836405A1 (en) 2012-11-22
KR20200118228A (ko) 2020-10-14
BR112013029336A2 (pt) 2020-08-11
EP2714006B1 (en) 2020-12-09
AU2019203067A1 (en) 2019-05-23
CA2836398C (en) 2021-12-14
CN109481394A (zh) 2019-03-19
CA3034552A1 (en) 2012-11-22
AU2012257490A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
JP2022105175A (ja) 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用
US20250064831A1 (en) Controlled release topical testosterone formulations and methods
US20250009756A1 (en) Male Testosterone Titration Methods, Male Intranasal Testosterone Bio-Adhesive Gel Formulations and Use Thereof for Treating Hypogonadism and TRT
US20240316063A1 (en) Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
HK1263036B (en) Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
HK1263036A1 (en) Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
HK1196287B (en) Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
HK1196287A (en) Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
HK1196261B (en) Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
EA039080B1 (ru) Интраназальные биоадгезивные тестостероновые составы в виде гелей и их применение для лечения мужского гипогонадизма

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160819

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170623

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170626

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191105